FDA trial shows sustained effect for Ozurdex on diabetic

The dexamethasone intraocular implant OZURDEX® (Allergan)
can bring about significant and visual improvement in patients
with diabetic macular oedema, with generally only transient
increases in IOP but with a high incidence of cataract in
phakic patients, said EURETINA president ,Francesco
Bandello MD, told attendees at an EURETINA free paper
session
He reported the pooled results of two FDA studies conducted
by the MEAD study group involving a total of 1048 patients
with diabetic macular oedema. The patients were randomised
into three groups to receive Ozurdex at a dosage of 0.7 mg or
0.35 mg , or sham treatment, with repeated injections when
indicated at intervals no shorter than six months.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.